Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms

Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms

Abstract Background Immunohistochemical (IHC) PD-L1 expression is commonly employed as predictive biomarker for checkpoint inhibitors in triple-negative breast cancer (TNBC). However, IHC evaluation methods are non-uniform and further studies are needed to optimize clinical utility. Methods We compa...

Full description

Bibliographic Details
Main Authors: Gudbjörg Sigurjonsdottir, Tommaso De Marchi, Anna Ehinger, Johan Hartman, Ana Bosch, Johan Staaf, Fredrika Killander, Emma Niméus
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Breast Cancer Research
Subjects:
Triple-negative breast cancer
PD-L1
Immunohistochemistry
SP142
22C3
Concordance
Online Access:https://doi.org/10.1186/s13058-023-01724-2

Internet

https://doi.org/10.1186/s13058-023-01724-2

Similar Items